Wide Ranks

GRCE

Grace Therapeutics, Inc.

3.37

Top Statistics
Market Cap 34 M Forward PE -2.83 Revenue Growth 0.00 %
Current Ratio 7.86 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.07 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 19 M Total Cash Per Share 1.91 Total Debt
Total Debt To Equity Current Ratio 7.86 Book Value Per Share 6.57
All Measures
Short Ratio 325.00 % Message Board Id finmb_47663822 Shares Short Prior Month 128931
Return On Equity -0.1856 City Princeton Uuid 3586da42-a4f2-34ee-a69c-42eb8983dee0
Previous Close 3.35 First Trade Date Epoch Utc 1 B Book Value 6.57
Beta 1.51 Volume 11184 Price To Book 0.5130
Last Split Date 1 B Fifty Two Week Low 1.98 Total Cash Per Share 1.91
Shares Short Previous Month Date 1 B Target Median Price 16.16 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Target Mean Price 14.97
Net Income To Common -11447000 Ask 3.21 Short Percent Of Float 0.0160
Implied Shares Outstanding 10 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 32070 Average Volume10days 32070 Total Cash 19 M
Next Fiscal Year End 1 B Held Percent Insiders 0.3839 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 3.35
Target Low Price 11.19 Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.16
Open 3.32 Free Cashflow -5580375 State NJ
Dividend Yield 0.00 % Return On Assets -0.1162 Time Zone Short Name EST
Trailing Eps -1.29 Day Low 3.32 Address1 103 Carnegie Center
Shares Outstanding 10 M Price Hint 4 Target High Price 17.56
Website https://www.acastipharma.com 52 Week Change 0.5530 Average Volume 35939
Forward Eps -1.26 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 761.80 % Last Split Factor 1:6 Regular Market Day High 3.44
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 3.60
Day High 3.44 Shares Short 127927 Regular Market Open 3.32
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0126 Operating Cashflow -9689000 Currency USD
Time Zone Full Name America/New_York Market Cap 34 M Is_nasdaq_100 False
Zip 08540 Quote Type EQUITY Industry Biotechnology
Long Name Grace Therapeutics, Inc. Regular Market Day Low 3.32 Held Percent Institutions 0.2139
Current Price 3.37 Address2 Suite 300 Enterprise To Ebitda -1.07
Financial Currency USD Current Ratio 7.86 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 4 M
Two Hundred Day Average 3.00 Enterprise Value 14 M Forward PE -2.83
Regular Market Volume 11184 Ebitda -13266000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.

It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.

The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.

The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.